0001906324-25-000151
SEC filingRevenue fell 3% to $1.31B, while gross margin improved to 47.3%; restructuring charges surged to $195M from Optimization Plan and Savanna exit.
For the six months ended June 29, 2025, total revenue decreased 3% to $1,306.7 million from $1,348.0 million in the prior year. The decline was primarily driven by lower COVID-19 revenue ($32.9M vs $69.1M) and the wind-down of the U.S. donor screening business (Donor Screening revenue down 61%). Labs revenue grew 4% to $742.7M, while Point of Care fell 13% to $263.9M. Gross margin improved to 47.3% from 45.1%, reflecting procurement cost savings. Operating loss narrowed to $148.1M from $1,875.5M, largely due to the absence of a $1.7B goodwill impairment. Restructuring charges surged to $195.0M from $53.5M, including costs from the new Optimization Plan and Savanna exit. Net loss improved to $268.1M from $1,853.7M.
North America (55% of revenue) declined 8% to $717.4M, hit by donor screening wind-down and lower respiratory sales. EMEA grew 6% to $176.2M, driven by broad-based gains. China was flat at $158.4M as Labs growth offset Point of Care weakness. Other (including Latin America and JPAC) rose 6% to $254.7M on Labs strength. Adjusted EBITDA in North America fell 7% to $394.0M, while EMEA jumped 47% and China rose 16%, reflecting cost control and mix.
Management announced the Optimization Plan in Q2 2025, expecting cumulative pretax charges of ~$100M through 2027 and net cost savings of ~$50M. The Savanna platform exit is expected to be substantially complete by H1 2027. Tariff uncertainties and competitive pricing pressures are noted risks. No specific numeric guidance was provided; the focus is on cost reduction, operational efficiency, and strategic refocusing on core diagnostics. Liquidity remains adequate with $151.7M cash and $397.3M available under the revolver.
As of June 29, 2025, QuidelOrtho held $151.7M in cash and equivalents, down from $98.3M at year-end 2024. Total debt stood at $2.61B, consisting of a Term Loan ($2.21B) and Revolving Credit Facility ($390M), with $534.2M classified as current. Shareholders' equity was $2.79B, a decrease from $2.98B due to net losses. Inventory (current) was $578.7M, and deferred revenue totaled $57.3M (current $40.2M, non-current $17.1M).
No purchase commitments or material contractual obligations were disclosed in the Notes. The company is involved in securities litigation and derivative lawsuits, but no loss estimate is provided.
During the six months ended June 29, 2025, the company made net debt repayments of $68.8M on the Term Loan and net borrowings of $192M on the Revolving Credit Facility, increasing total debt by $123.2M. Capital expenditures were $93.7M (7.2% of revenue), primarily for property, plant, and equipment. No share buybacks or dividends were reported.
Note 4 provides segment-level revenue and Adjusted EBITDA for three months ended June 29, 2025. North America generated $310.7M (51% of total), with Adjusted EBITDA of $159.7M (51.4% margin). EMEA contributed $87.3M (14%), China $83.4M (14%), and Other $132.5M (21%). YoY changes: North America -11.3%, EMEA +7.6%, China +2.2%, Other +6.7%. Segment Adjusted EBITDA margins ranged from 21% (EMEA) to 51.4% (North America).
Net loss of -$268.1M was significantly smaller than the prior period's -$1,853.7M, largely due to absence of goodwill impairment ($1,743.9M in 2024). Operating cash flow turned positive at $18.8M versus -$98.6M, supported by non-cash charges (depreciation $217.4M, asset write-off $151.4M) and favorable working capital movements (accounts receivable +$24.7M, income taxes payable +$57.5M). However, inventory built by $102.6M and payables declined, partially offsetting. Capex of $93.7M (down 7.6% YoY) consumed 498% of CFO, indicating heavy investment relative to operating cash generation. No dividends or share repurchases were paid. Financing activities provided $120.9M, mainly from revolving credit facility draws ($192.0M) net of long-term debt payments ($72.0M). The cash conversion cycle expanded due to inventory growth, warranting monitoring.
Anomalies include a $151.4M non-cash asset write-off related to restructuring, which inflates CFO but does not represent cash generation. Additionally, the tax payable swing provided a significant $57.5M boost to operating cash flow.